FIND DRUGS:

BRAND NAME GENERIC NAME INDICATION MANUFACTURERS COMPARE DRUGS

Male Reproductive Cancers Resource Center

Viewpoints

Circumcision May Reduce Prostate Cancer Risk

Circumcision May Reduce Prostate Cancer Risk

The evidence continues to grow that circumcision may help lower a man's overall risk for prostate cancer.

A Fellow's Perspective: Overview of the ASCO 2014 Plenary Session

A Fellow's Perspective: Overview of the ASCO 2014 Plenary Session

Matt Zibelman, MD, provides his view on the research presented during the plenary session at the 2014 ASCO Annual Meeting.

Feature Articles

Primary Androgen-Deprivation Therapy (ADT) for Localized Prostate Cancer: Potential for Harm May Outweigh Benefit in Low-Risk Disease

Primary Androgen-Deprivation Therapy (ADT) for Localized Prostate Cancer: Potential for Harm May Outweigh Benefit in Low-Risk Disease

Although ADT remains an important treatment, its use as primary therapy in low-risk prostate cancer seems increasingly ill advised.

Male Reproductive Cancers Resources

More Male Reproductive Cancers Resources

Managing Bone Health in Prostate Cancer

This fact sheet answers some common questions about prostate cancer, bone scan, and metastasis.

Prostate Cancer: What to Know About Screening, Diagnosis

This fact sheet reviews current prostate cancer screening tests, guidelines, PSA, and risk factors.

Testicular Cancer Fact Sheet

This fact sheet provides information on symptoms, pain, causes, and treatments for testicular, testicle cancer.

ZYDELIG® (idelalisib) for Relapsed Follicular B-cell Non-Hodgkin Lymphoma (FL)

ZYDELIG® (idelalisib) for Relapsed Follicular B-cell Non-Hodgkin Lymphoma (FL)

This slideshow reviews drug information for ZYDELIG® (idelalisib), indicated for relapsed follicular non-Hodgkin lymphoma (FL).

Table of Contents

Slide 3: Indication, Dosage, ...

ZYDELIG® (idelalisib) for Relapsed Chronic Lymphocytic Leukemia

ZYDELIG® (idelalisib) for Relapsed Chronic Lymphocytic Leukemia

This slideshow reviews drug information for ZYDELIG® (idelalisib), indicated for relapsed chronic lymphoma.

Table of Contents

Slide 3: Indication, Dosage, and Administration
Slide ...

ZYKADIA™ (ceritinib)

ZYKADIA™ (ceritinib)

This slideshow reviews drug information for ZYKADIA™ (ceritinib), indicated for anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC).

Table ...

PURIXAN® (mercaptopurine [6-MP] oral suspension)

PURIXAN® (mercaptopurine [6-MP] oral suspension)

This slideshow reviews drug information for PURIXAN® (mercaptopurine [6-MP] oral suspension), indicated for acute lymphoblastic leukemia.

Table of Contents

Slide 3: Indication, ...

SYLATRON® (peginterferon alfa-2b)

SYLATRON® (peginterferon alfa-2b)

Review slide-by-slide drug information for SYLATRON® (peginterferon alfa-2b) for treatment of melanoma.

Table of Contents

Slide 3: Indication, Dosage, and Administration
Slide 8: ...

Sign Up for Free e-newsletters

CTA Community Poll

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs